TY - JOUR
T1 - Hepatic vein embolization after portal vein embolization to induce additional liver hypertrophy in patients with metastatic colorectal carcinoma
AU - Niekamp, Andrew S.
AU - Huang, Steven Y.
AU - Mahvash, Armeen
AU - Odisio, Bruno C.
AU - Ahrar, Kamran
AU - Tzeng, Ching Wei D.
AU - Vauthey, Jean Nicolas
N1 - Publisher Copyright:
© 2020, European Society of Radiology.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/7/1
Y1 - 2020/7/1
N2 - Objectives: To assess the effect of salvage hepatic vein embolization (HVE) on the volume of the future liver remnant (FLR) for patients with metastatic colorectal cancer (mCRC) and inadequate hypertrophy following initial portal vein embolization (PVE). Methods: From April 2011 to October 2018, 9 patients with mCRC underwent HVE following PVE. The right or middle hepatic vein was embolized with coils and/or vascular plugs. Liver volumes were calculated at baseline, following PVE, and following HVE, in order to assess the hypertrophic effect of PVE and HVE on the FLR. Results: Nine patients underwent HVE (n = 3, right HVE; n = 6, middle HVE) because of inadequate FLR hypertrophy following PVE. The standardized FLR increased from 0.16 (median, range 0.08–0.24) at baseline to 0.22 (median, range 0.13–0.29) following PVE (p = 0.0005) to 0.26 (median, range 0.19–0.37) following HVE (p = 0.0050). HVE was performed 40 days (median, range 19–128 days) following PVE, and assessment of FLR hypertrophy was performed 41 days (median, range 19–92 days) following HVE. Four of nine patients underwent hepatectomy; 5 patients failed to undergo hepatectomy (n = 3, inadequate hypertrophy; n = 1, disease progression; n = 1, portal hypertension). One patient required repeat HVE due to a patent accessory vein. Conclusions: Salvage HVE is an effective technique to induce additional FLR hypertrophy in patients with mCRC and inadequate FLR after initial PVE. Key Points: • Hepatic vein embolization is effective to induce additional liver hypertrophy in surgical patients with metastatic colorectal carcinoma and inadequate hypertrophy after portal vein embolization. • Increases in future liver remnant volume are feasible in patients who receive hepatotoxic neoadjuvant systemic therapy for metastatic colorectal carcinoma. • Sequential portal vein embolization and hepatic vein embolization can be a viable technique to induce liver hypertrophy in patients with small baseline future liver remnant volumes (< 20%).
AB - Objectives: To assess the effect of salvage hepatic vein embolization (HVE) on the volume of the future liver remnant (FLR) for patients with metastatic colorectal cancer (mCRC) and inadequate hypertrophy following initial portal vein embolization (PVE). Methods: From April 2011 to October 2018, 9 patients with mCRC underwent HVE following PVE. The right or middle hepatic vein was embolized with coils and/or vascular plugs. Liver volumes were calculated at baseline, following PVE, and following HVE, in order to assess the hypertrophic effect of PVE and HVE on the FLR. Results: Nine patients underwent HVE (n = 3, right HVE; n = 6, middle HVE) because of inadequate FLR hypertrophy following PVE. The standardized FLR increased from 0.16 (median, range 0.08–0.24) at baseline to 0.22 (median, range 0.13–0.29) following PVE (p = 0.0005) to 0.26 (median, range 0.19–0.37) following HVE (p = 0.0050). HVE was performed 40 days (median, range 19–128 days) following PVE, and assessment of FLR hypertrophy was performed 41 days (median, range 19–92 days) following HVE. Four of nine patients underwent hepatectomy; 5 patients failed to undergo hepatectomy (n = 3, inadequate hypertrophy; n = 1, disease progression; n = 1, portal hypertension). One patient required repeat HVE due to a patent accessory vein. Conclusions: Salvage HVE is an effective technique to induce additional FLR hypertrophy in patients with mCRC and inadequate FLR after initial PVE. Key Points: • Hepatic vein embolization is effective to induce additional liver hypertrophy in surgical patients with metastatic colorectal carcinoma and inadequate hypertrophy after portal vein embolization. • Increases in future liver remnant volume are feasible in patients who receive hepatotoxic neoadjuvant systemic therapy for metastatic colorectal carcinoma. • Sequential portal vein embolization and hepatic vein embolization can be a viable technique to induce liver hypertrophy in patients with small baseline future liver remnant volumes (< 20%).
KW - Colorectal neoplasms
KW - Hepatic veins
KW - Hypertrophy
KW - Portal vein
KW - Therapeutic embolization
UR - http://www.scopus.com/inward/record.url?scp=85081625672&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081625672&partnerID=8YFLogxK
U2 - 10.1007/s00330-020-06746-4
DO - 10.1007/s00330-020-06746-4
M3 - Article
C2 - 32144462
AN - SCOPUS:85081625672
SN - 0938-7994
VL - 30
SP - 3862
EP - 3868
JO - European Radiology
JF - European Radiology
IS - 7
ER -